Aristotle Atlantic Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Aristotle Atlantic Partners’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-24,099	Closed	-$3.77M	–	105
2020 Q4	$3.77M	Buy	24,099 +2,401	+11%	+$309K	0.29%	56
2020 Q3	$2.48M	Buy	21,698 +1,563	+8%	+$169K	0.22%	60
2020 Q2	$2.26M	Buy	20,135 +5,397	+37%	+$573K	0.22%	60
2020 Q1	$1.32M	Buy	14,738 +5,324	+57%	+$523K	0.2%	62
2019 Q4	$1.02M	Buy	9,414 +1,262	+15%	+$135K	0.13%	72
2019 Q3	$798K	Buy	8,152 +3,976	+95%	+$448K	0.23%	72
2019 Q2	$547K	Buy	+4,176	New	+$538K	0.16%	76

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aristotle Atlantic Partners's ALXN Position: Q1 2021 in Review

Aristotle Atlantic Partners sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 24,099 shares — an estimated $3.77M sold.

Aristotle Atlantic Partners first reported a position in ALXN in Q2 2019 and held it in 7 quarters. The position peaked at $3.77M in Q4 2020. 752 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

Aristotle Atlantic Partners reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Aristotle Atlantic Partners sold 24,099 Alexion Pharmaceuticals shares in Q1 2021, an estimated $3.77M.
Aristotle Atlantic Partners first reported a position in Alexion Pharmaceuticals in Q2 2019 and held it in 7 quarters.
Aristotle Atlantic Partners's Alexion Pharmaceuticals position peaked at $3.77M in Q4 2020.
752 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Aristotle Atlantic Partners's 13F filing for Q1 2021, filed 17 May 2021.